3 Clinics Recognized for Successful First Phase of CHANGE Program
Toronto | On April 28, 2015, at Metabolic Syndrome Canada's annual stakeholder meeting, Dr. Khush Jeejeebhoy formally recognized the first three clinics to successfully implement the CHANGE Program.
On hand were doctors, dietitians, kinesiologists and administrators from the Edmonton Oliver Primary Care Network in Edmonton, L'unité de médecine familiale at Université Laval in Québec City, and the Polyclinic Family and Specialty Medicine Facility in Toronto, all of whom participated in the CHANGE feasibility study.
From Left: Alison Craig, Lindsey Ertman, Cynthia Dimaano, Serena Humphries, Dr. Khursheed Jeejeebhoy. Missing: Dr. Doug Klein
From Left: Lucie Brunelle, Dr. Angelo Tremblay, Caroline Doyon, Dr. Jeejeebhoy, Dr. Caroline Rhéaume. Missing: Dr. Marie-Josee Filion
From Left: Anna Skomorovskaia, Sharaf Malik-Aslanova, Sonia Plyam, Dr. Lew Pliamm, Dr. Jeejeebhoy. Missing: Leslie Sole
Since 2012, more than 300 patients at the three clinics adopted the CHANGE Program, with promising initial results.
“The clinics’ support of our unique lifestyle intervention model has been essential in demonstrating its feasibility in the family medicine clinic setting,” said Dr. Jeejeebhoy, speaking on behalf of the CHANGE operations team. “Each health professional deserves our thanks for the time and energy they’ve invested in not only helping patients make lasting improvements to their health with the CHANGE Program, but also capturing and reporting important research data that will be instrumental to future phases of the program.”
During the meeting, each clinic also presented the lessons learned from the program, including patient outcomes and feedback on program managment in the clinic setting. “We are very encouraged by what we heard today,” said Dr. Jeejeebhoy. “It confirmed that we are on the right track and we’re excited to incorporate their findings into how other clinics can successfully implement the CHANGE Program for their patients.”
Each of the clinics continues to work with patients as they complete the 12 months follow-up. Final results from the feasibility study will be compiled beginning in December.